Are multiple markers the future of prostate cancer diagnostics?

Prostate specific antigen (PSA) is the most successful and widely employed cancer serum marker in use today. There is growing evidence that the introduction of wide PSA screening and earlier detection can result in decreased cancer mortality associated with a decline in metastatic disease. PSA circu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Biochemistry 2004-07, Vol.37 (7), p.519-528
Main Authors: Mikolajczyk, Stephen D., Song, Yong, Wong, James R., Matson, Robert S., Rittenhouse, Harry G.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - blood
Cell Adhesion Molecules - blood
Cytokines - blood
Forecasting
Growth Substances - blood
Humans
Isoenzymes - blood
Isoenzymes - genetics
Isoenzymes - metabolism
Male
Markers
Models, Biological
Prostate cancer
Prostate-specific antigen
Prostate-Specific Antigen - blood
Prostate-Specific Antigen - genetics
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - pathology
Proteomics
Tissue Kallikreins - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate specific antigen (PSA) is the most successful and widely employed cancer serum marker in use today. There is growing evidence that the introduction of wide PSA screening and earlier detection can result in decreased cancer mortality associated with a decline in metastatic disease. PSA circulates in a number of distinct forms. Measurement of these in addition to total PSA significantly increases diagnostic utility. Diagnostic utility is likely to be further increased by adding kallikreins, cytokines, growth factors, receptors and cellular adhesion factors to the biomarker panel. The need for multiple markers reflects the multidimensional nature of prostate disease which ranges from metastatic cancer to indolent cancer to benign hyperplasia and inflammation, all of which require distinct treatments and medical interventions.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2004.05.016